Immunotherapy with an anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin was associated with a significantly improved outcome compared with standard therapy in patients with high-risk neuroblastoma (41). Here, IL2 is linked to neuroblastoma.